Metastatic Breast Cancer

“My patients, my heroes” is a special series in my blog that I dedicate to my patients. It launched in May with the story of my patient, Melissa, titled “Beating the Odds.”

The FDA granted priority review to oral paclitaxel and encequidar for the treatment of metastatic breast cancer.

Research exploring novel targeted agents for patients with metastatic breast cancer is mounting and spurring excitement in the oncology field.

Cancer can be a very personal and individualized disease, with predictable and unpredictable outcomes.

Early local therapy did not extend survival in women with de novo metastatic breast cancer and intact primary tumors, according to results from a randomized phase 3 study presented at ASCO20 Virtual Scientific Program.

In this video, Sara M. Tolaney, MD, MPH, breast medical oncologist at Dana Farber Cancer Institute, shared her perspectives on data from the TBCRC 048 trial presented during the ASCO20 Virtual Scientific Program.

Heterogeneity of serial circulating tumor DNA appeared associated with progressive disease among patients with metastatic breast cancer, according to study findings presented during the ASCO20 Virtual Scientific Program.

Early local therapy did not prolong survival among women with de novo metastatic breast cancer and intact primary tumors, according to randomized phase 3 study results presented during the ASCO20 Virtual Scientific Program.

The FDA granted priority review to the following therapies in development for oncology and hematology indications:

Following the promising findings of the second interim analysis of the randomized phase 3 SOPHIA trial — presented at San Antonio Breast Cancer Symposium in December 2019 — the manufacturer of the investigational agent, margetuximab, submitted a biologics license application for use in patients with metastatic HER2-positive breast cancer.